Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DURECT Corporation
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
The latest US FDA approval news from the Pink Sheet’s US FDA Performance Tracker
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
- Specialty Pharmaceuticals